6 articles with Hexagon Bio
Hexagon Bio Raises $77.3 Million Series B Financing and Strengthens Leadership to Expand Novel Computational Discovery Platform and Advance Microbial Genome-Derived Small Molecules
Hexagon Bio, a biopharmaceutical company pioneering the discovery of medicines encoded in the global metagenome, today announced that it has raised a $77.3 million Series B financing and made key appointments to its leadership team. Existing investors, including The Column Group, Two Sigma Ventures, 8VC, and Nextech, participated in the Series B round, joined by additional new investors, including Canada Pension Plan Investment Board (CPP Investments).
Money on the Move: September 22 – 28
9/29/2021These life sciences companies are falling into some cold, hard investment cash.
Kunwoo Lee has uncloaked his solution to the gene-editing “delivery problem” with $26 million in Series A funds for his company, GenEdit.
Hexagon Bio Raises $61 Million to Advance Novel Small-Molecule Medicines Mined from Microbial Genomes
Hexagon Bio today announced that it has raised $61 million to fuel the continued development of its platform to design and develop new therapeutics mined from microbial genomes.
BioSpace is proud to present its NextGen Bio “Class of 2021,” a list of up-and-coming life science startups in North America that recently launched.
Hexagon Bio, a California-based biotechnology company turning nature’s DNA into medicines for cancers and infectious diseases with unmet needs, will move into clinical research with $47 million in Series A financing.